R&D turbulence at Bristol Myers now includes the end of a $650M alliance and the departure of a top research champion

Bioregnum Opinion Column by John Carroll

This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.

The news arrives amid a turbulent R&D stage…